171 related articles for article (PubMed ID: 11903325)
41. Renal and vascular effects of chronic endothelin receptor antagonism in malignant hypertensive rats.
Li JS; Schürch W; Schiffrin EL
Am J Hypertens; 1996 Aug; 9(8):803-11. PubMed ID: 8862227
[TBL] [Abstract][Full Text] [Related]
42. Effects of nonpeptide endothelin receptor antagonists in rats with reduced renal mass.
Clozel M; Qiu C; Osterwalder R; Roeckel A; Bruneval P; Heudes D; Clozel JP
J Cardiovasc Pharmacol; 1999 Apr; 33(4):611-8. PubMed ID: 10218732
[TBL] [Abstract][Full Text] [Related]
43. Simvastatin reverses target organ damage and oxidative stress in Angiotensin II hypertension: comparison with apocynin, tempol, and hydralazine.
Rugale C; Delbosc S; Mimran A; Jover B
J Cardiovasc Pharmacol; 2007 Sep; 50(3):293-8. PubMed ID: 17878758
[TBL] [Abstract][Full Text] [Related]
44. Combined inhibition of angiotensin II and endothelin suppresses the brain natriuretic peptide response to developing heart failure.
Rademaker MT; Charles CJ; Espiner EA; Frampton CM; Nicholls MG; Richards AM
Clin Sci (Lond); 2004 Jun; 106(6):569-76. PubMed ID: 14723602
[TBL] [Abstract][Full Text] [Related]
45. Endothelin ET(B) receptors contribute to sex differences in blood pressure elevation in angiotensin II hypertensive rats on a high-salt diet.
Kittikulsuth W; Looney SW; Pollock DM
Clin Exp Pharmacol Physiol; 2013 Jun; 40(6):362-70. PubMed ID: 23713708
[TBL] [Abstract][Full Text] [Related]
46. Beneficial hemodynamic effects of bosentan, a mixed ET(A) and ET(B) receptor antagonist, in portal hypertensive rats.
Sogni P; Moreau R; Gomola A; Gadano A; Cailmail S; Calmus Y; Clozel M; Lebrec D
Hepatology; 1998 Sep; 28(3):655-9. PubMed ID: 9731554
[TBL] [Abstract][Full Text] [Related]
47. Total peripheral conductance mediates antihypertensive effect of nonpeptide mixed endothelin receptor antagonist in deoxycorticosterone acetate-salt hypertensive rats.
Yu M; Gopalakrishnan V; McNeill JR
Am J Hypertens; 1999 Aug; 12(8 Pt 1):845-8. PubMed ID: 10480481
[TBL] [Abstract][Full Text] [Related]
48. Reactivity of mesenteric arteries from fructose hypertensive rats to endothelin-1.
Verma S; Skarsgard P; Bhanot S; Yao L; Laher I; McNeill JH
Am J Hypertens; 1997 Sep; 10(9 Pt 1):1010-9. PubMed ID: 9324107
[TBL] [Abstract][Full Text] [Related]
49. Additional hypotensive effect of endothelin-1 receptor antagonism in hypertensive dogs under angiotensin-converting enzyme inhibition.
Donckier JE; Massart PE; Hodeige D; Van Mechelen H; Clozel JP; Laloux O; Ketelslegers JM; Charlier AA; Heyndrickx GR
Circulation; 1997 Aug; 96(4):1250-6. PubMed ID: 9286956
[TBL] [Abstract][Full Text] [Related]
50. The endothelin receptor antagonist, bosentan, in combination with the cyclooxygenase inhibitor, diclofenac, counteracts pulmonary hypertension in porcine endotoxin shock.
Wanecek M; Rudehill A; Hemsén A; Lundberg JM; Weitzberg E
Crit Care Med; 1997 May; 25(5):848-57. PubMed ID: 9187606
[TBL] [Abstract][Full Text] [Related]
51. Comparison of angiotensin II-induced blood pressure and structural changes in Fischer 344 and Wistar Kyoto rats.
Blanc J; Lacolley P; Laurent S; Elghozi JL
Clin Exp Pharmacol Physiol; 2004 Jul; 31(7):466-73. PubMed ID: 15236636
[TBL] [Abstract][Full Text] [Related]
52. Endothelin B receptor-mediated vasoconstriction induced by endothelin A receptor antagonist.
Zhang Y; Oliver JR; Horowitz JD
Cardiovasc Res; 1998 Sep; 39(3):665-73. PubMed ID: 9861310
[TBL] [Abstract][Full Text] [Related]
53. Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling.
Fraccarollo D; Hu K; Galuppo P; Gaudron P; Ertl G
Circulation; 1997 Dec; 96(11):3963-73. PubMed ID: 9403621
[TBL] [Abstract][Full Text] [Related]
54. Aortic smooth muscle cell phenotypic modulation and fibrillar collagen deposition in angiotensin II-dependent hypertension.
Rossi GP; Cavallin M; Belloni AS; Mazzocchi G; Nussdorfer GG; Pessina AC; Sartore S
Cardiovasc Res; 2002 Jul; 55(1):178-89. PubMed ID: 12062721
[TBL] [Abstract][Full Text] [Related]
55. Endothelin-1 receptor antagonism does not influence myocardial function in hypertensive dogs.
Massart PE; Hodeige D; Van Mechelen H; Heyndrickx GR; Donckier J
Eur J Clin Invest; 1998 Oct; 28(10):798-806. PubMed ID: 9792992
[TBL] [Abstract][Full Text] [Related]
56. Endothelin and endothelin antagonists in hypertension.
Schiffrin EL
J Hypertens; 1998 Dec; 16(12 Pt 2):1891-5. PubMed ID: 9886874
[TBL] [Abstract][Full Text] [Related]
57. Combined inhibition of endothelin and angiotensin II receptors blocks volume load-induced cardiac hormone release.
Leskinen H; Vuolteenaho O; Ruskoaho H
Circ Res; 1997 Jan; 80(1):114-23. PubMed ID: 8978330
[TBL] [Abstract][Full Text] [Related]
58. Differential effects of endothelin-1 antagonists on erythropoietin-induced hypertension in renal failure.
Brochu E; Lacasse S; Larivière R; Kingma I; Grose JH; Lebel M
J Am Soc Nephrol; 1999 Jul; 10(7):1440-6. PubMed ID: 10405199
[TBL] [Abstract][Full Text] [Related]
59. Endothelin-1 is involved in stretch-induced early activation of B-type natriuretic peptide gene expression in atrial but not in ventricular myocytes: acute effects of mixed ET(A)/ET(B) and AT1 receptor antagonists in vivo and in vitro.
Magga J; Vuolteenaho O; Marttila M; Ruskoaho H
Circulation; 1997 Nov; 96(9):3053-62. PubMed ID: 9386175
[TBL] [Abstract][Full Text] [Related]
60. Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes.
Tikkanen I; Tikkanen T; Cao Z; Allen TJ; Davis BJ; Lassila M; Casley D; Johnston CI; Burrell LM; Cooper ME
J Hypertens; 2002 Apr; 20(4):707-14. PubMed ID: 11910307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
